Undervalued Biotechnology Stocks on NAS July 2025

July 13, 2025

Biotechnology

Biotechnology and Biopharmaceutical companies are engaged in research, discovery, development, and production of innovative drug and drug-related technologies.

NASDAQ

The National Association of Securities Dealers Automated Quotations (Nasdaq) located in New York City, is the most active stock exchange by volume in the United States.

Our Valuation

A stock is considered undervalued if it trades at a discount to our valuation. To determine a stock’s intrinsic value, we developed an algorithm that uses 6 valuation models to determine the value of a company.* To learn more about stockcalc’s valuation methods, click here.

Undervalued Biotechnology stocks

Stocks in this category are held primarily for capital appreciation.

For an in-depth look at the fundamentals and valuation of each company, try the stockcalc platform free for 30 days.

SymbolNameClose Price ($)Valuation ($)Difference (%)Average Vol (30D)Market Cap ($M)Yield (%)P/E Ratio
PLRZ Polyrizon 0.91 15.43 1589.48 5151846 0 0.00 0.0
NCNA NuCana 0.04 0.26 634.64 122492429 0 0.00 0.0
VOR Vor Biopharma 0.20 0.85 324.46 5185683 25 0.00 0.0
BOLD Boundless Bio 1.10 3.75 241.22 77341 25 0.00 0.1
IPSC Century Therapeutics 0.53 1.76 234.76 726620 45 0.00 0.0
PRME Prime Medicine 1.18 3.92 231.14 2398302 155 0.00 0.0
RANI Rani Therapeutics Hldgs 0.56 1.83 226.56 849320 19 0.00 0.0
GBIO Generation Bio 0.38 1.23 226.47 467738 25 0.00 0.0
CCCC C4 Therapeutics 1.25 3.82 205.22 997267 89 0.00 0.0
CERO CERo Therapeutics Hldgs 0.44 1.29 190.84 761321 2 0.00 0.0
All data provided as at market close May 29, 2025.

Company Details

Polyrizon

PLRZ:NAS

Close Price

0.91

Our Valuation

15.43

% Difference

1589.48

Market Cap ($M)

0

P/E Ratio

0.0

Polyrizon Ltd is a clinical development stage biotech company specializing in the development of nasal gels to provide preventative treatment to protect against a wide cross-section of viruses, including certain variants of COVID-19 that are also considered to cause more infections and spread faster than the original strain of the virus (the CDC expects that additional variants of the virus will continue to occur), influenza, allergens, and other toxins.

Access the stockcalc valuation


NuCana

NCNA:NAS

Close Price

0.04

Our Valuation

0.26

% Difference

634.64

Market Cap ($M)

0

P/E Ratio

0.0

NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.

Access the stockcalc valuation


Vor Biopharma

VOR:NAS

Close Price

0.20

Our Valuation

0.85

% Difference

324.46

Market Cap ($M)

25

P/E Ratio

0.0

Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.

Access the stockcalc valuation


Boundless Bio

BOLD:NAS

Close Price

1.10

Our Valuation

3.75

% Difference

241.22

Market Cap ($M)

25

P/E Ratio

0.1

Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.

Access the stockcalc valuation


Access our valuation for these companies and 9,000+ more

Try the stockcalc platform free for 30 days

Sign Up

Century Therapeutics

IPSC:NAS

Close Price

0.53

Our Valuation

1.76

% Difference

234.76

Market Cap ($M)

45

P/E Ratio

0.0

Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities.

Access the stockcalc valuation


Prime Medicine

PRME:NAS

Close Price

1.18

Our Valuation

3.92

% Difference

231.14

Market Cap ($M)

155

P/E Ratio

0.0

Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.

Access the stockcalc valuation


Rani Therapeutics Hldgs

RANI:NAS

Close Price

0.56

Our Valuation

1.83

% Difference

226.56

Market Cap ($M)

19

P/E Ratio

0.0

Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides.

Access the stockcalc valuation


Generation Bio

GBIO:NAS

Close Price

0.38

Our Valuation

1.23

% Difference

226.47

Market Cap ($M)

25

P/E Ratio

0.0

Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications.

Access the stockcalc valuation


C4 Therapeutics

CCCC:NAS

Close Price

1.25

Our Valuation

3.82

% Difference

205.22

Market Cap ($M)

89

P/E Ratio

0.0

C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases.

Access the stockcalc valuation


CERo Therapeutics Hldgs

CERO:NAS

Close Price

0.44

Our Valuation

1.29

% Difference

190.84

Market Cap ($M)

2

P/E Ratio

0.0

CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.

Access the stockcalc valuation


Access thousands of valuation reports

Try the stockcalc platform for 30 days for unlimited access to our valuation reports

Sign Up
Polyrizon and NuCana are the most undervalued Biotechnology stocks on the NAS. See the full list on the blog: https://www.stockcalc.com/Blog/undervalued-biotechnology-stocks-nas-july-2025
Polyrizon $PLRZ and NuCana $NCNA are the most undervalued Biotechnology stocks on the #NAS. See the full list: https://www.stockcalc.com/Blog/undervalued-biotechnology-stocks-nas-july-2025
Polyrizon and NuCana are the most undervalued Biotechnology stocks on the NAS. See the full list on the blog: https://www.stockcalc.com/Blog/undervalued-biotechnology-stocks-nas-july-2025

Copyright © 2016- Patchell Brook Equity Analytics Inc. All rights reserved.

Risk Disclosure: Equities trading and trading of all markets, exchanges and instruments contains substantial risk and is not for every investor. An investor could potentially lose all or more than the initial investment. Risk capital is money that can be lost without jeopardizing ones’ financial security or life style. Only risk capital should be used for trading and only those with sufficient risk capital should consider trading. Past performance is not necessarily indicative of future results. View full risk information here.